Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Assets (2021 - 2025)

InMed Pharmaceuticals' Non-Current Assets history spans 5 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 20.76% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $10.5 million, down 16.6%, while the annual FY2025 figure was $2.7 million, 13.42% down from the prior year.
  • Non-Current Assets reached $2.4 million in Q4 2025 per INM's latest filing, down from $2.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $6.9 million in Q4 2021 to a low of $1.4 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $3.3 million, with a median of $3.0 million recorded in 2022.
  • The largest YoY upside for Non-Current Assets was 125.13% in 2022 against a maximum downside of 57.81% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $6.9 million in 2021, then crashed by 57.81% to $2.9 million in 2022, then increased by 18.73% to $3.4 million in 2023, then decreased by 11.99% to $3.0 million in 2024, then dropped by 20.76% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Non-Current Assets are $2.4 million (Q4 2025), $2.6 million (Q3 2025), and $2.7 million (Q2 2025).